Godrej Agrovet Limited · NSE:GODREJAGRO
Godrej Agrovet — Q2 FY22 Earnings Presentation
22 slides from Godrej Agrovet's earnings presentation, Nov 9, 2021
Slide 1: Cover letter to BSE and NSE: Presentation to Investors & Analysts
Date: November 9, 2021 To, To, BSE Limited National Stock Exchange of India Limited P. J. Towers, Dalal Street, Fort Exchange Plaza, Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai-400 051 Ref.: BSE Scrip Code No. “540743” Ref.: “GODREJAGRO” Sub: Presentation to Investors & Analysts D
Slide 2: Godrej Agrovet Limited Q2FY22 & H1FY22 Performance Update
GODREJ AGROVET LIMITED Q2FY22 & H1FY22 PERFORMANCE UPDATE
Slide 3: Godrej Agrovet Limited (GAVL) – ESG Update
GODREJ AGROVET LIMITED (GAVL) – ESG UPDATE 2 I Godrej Agrovet
Slide 4: Striding Towards a Net Zero Future
STRIDING TOWARDS A NET ZERO FUTURE • Overachieved our renewable capacity addition target of 30% by 2020 • Currently at 70% and will achieve goal of 90% Renewable Energy (RE) usage by 2025 • Achieved more than 400% water positivity i.e. for every litre of water we withdraw, we add 4 litres back to th
Slide 5: Ambitious Global Commitments & Affiliations
AMBITIOUS GLOBAL COMMITMENTS & AFFILIATIONS • Member of the World Business • Member of the Global • Committed to the global Science Council for Sustainable Agribusiness Alliance, of which Based Targets initiative (SBTi) to Development Mr. Nadir B. Godrej is also reduce our emissions in line with • S
Slide 6: Godrej Agrovet Limited (GAVL) Performance Highlights
GODREJ AGROVET LIMITED (GAVL) PERFORMANCE HIGHLIGHTS 5 I Godrej Agrovet
Slide 7: Q2FY22 Financials – Key Highlights
Q2FY22 FINANCIALS – KEY HIGHLIGHTS Particulars Standalone Consolidated (Rs crore, unless stated) Q2FY22 Q2FY21 Growth Q2FY22 Q2FY21 Growth Total Income 1,699.3 1,256.0 35.3% 2,159.7 1,732.2 24.7% Earnings before interest, tax and 166.2 135.9 22.3% 196.1 181.5 8.0% Depreciation (EBITDA) EBITDA Margin
Slide 8: H1FY22 Financials – Key Highlights
H1FY22 FINANCIALS – KEY HIGHLIGHTS Particulars Standalone Consolidated (Rs crore, unless stated) H1FY22 H1FY21 Growth H1FY22 H1FY21 Growth Total Income 3,258.8 2,419.6 34.7% 4,162.9 3,294.7 26.4% Earnings before interest, tax 327.1 278.2 17.6% 376.0 355.7 5.7% and Depreciation (EBITDA) EBITDA Margin
Slide 9: H1FY22 Segment-wise Revenue and PBIT
H1FY22 SEGMENT-WISE REVENUE AND PBIT Segment Revenue Mix(1) Profit before interest and taxes (2) Poultry & processed Dairy Poultry & food -3.9% processed Others food 0.3% 8.6% 0.6% Animal Feed, Dairy 34.3% 12.5% Animal Feed 48.5% Crop Protection Crop 38.1% Protection 14.2% Oil Palm Oil Palm Plantati
Slide 10: Segment-wise Performance Update
SEGMENT-WISE PERFORMANCE UPDATE 9 I Godrej Agrovet
Slide 11: Animal Feed
ANIMAL FEED Leading compound feed play across Cattle (Milk), Broiler, Layer, Fish and Shrimp feed in India Particulars Q2FY22 Q2FY21 Growth H1FY22 H1FY21 Growth Sales Volume (tons) 3,37,609 2,79,906 20.6% 6,54,446 5,47,655 19.5% Segment Revenue (Cr) 1,134.1 762.3 48.8% 2,135.4 1,510.3 41.4% Segment
Slide 12: Oil Palm Business
OIL PALM BUSINESS Largest domestic producer of Crude Palm oil and Palm Kernel Oil Particulars Q2FY22 Q2FY21 Growth H1FY22 H1FY21 Growth Segment Revenue (Cr) 401.4 293.2 36.9% 690.2 450.5 53.2% Segment Result (Cr) 78.1 41.4 88.5% 110.7 47.9 131.1% Segment Margin (%) 19.5% 14.1% 16.0% 10.6% • Segment
Slide 13: Crop Protection Business
CROP PROTECTION BUSINESS Agrochemical products produced cater to the entire crop lifecycles Particulars Q2FY22 Q2FY21 Growth H1FY22 H1FY21 Growth Segment Revenue (Cr) 154.0 176.3 (12.6%) 394.5 384.5 2.6% Segment Result (Cr) 37.6 49.5 (24.0%) 101.6 109.9 (7.6%) Segment Margin (%) 24.4% 28.1% 25.8% 28
Slide 14: Astec Lifesciences
ASTEC LIFESCIENCES Manufactures a wide range of agrochemical active ingredients and pharmaceutical intermediates Particulars Q2FY22 Q2FY21 Growth H1FY22 H1FY21 Growth Revenues (Cr.) 102.6 155.0 (33.8%) 231.2 266.9 (13.4%) EBITDA (Cr.) 22.0 31.4 (29.9%) 47.5 60.9 (22.0%) EBITDA Margin (%) 21.4% 20.3%
Slide 15: Creamline Dairy
CREAMLINE DAIRY Particulars Q2FY22 Q2FY21 Growth H1FY22 H1FY21 Growth Revenue (Cr.) 284.1 259.0 9.7% 550.6 495.4 11.1% EBITDA (Cr.) 4.1 11.2 (63.3%) 1.0 21.5 (95.3%) EBITDA Margin (%) 1.4% 4.3% 0.2% 4.3% • Increase in volumes of value added products and milk has enabled a revenue growth of 9.7% in Q
Slide 16: Godrej Tyson Foods Limited and ACI Godrej Agrovet joint venture
GODREJ TYSON FOODS LIMITED Particulars Q2FY22 Q2FY21 Growth H1FY22 H1FY21 Growth Revenue (Cr) 200.9 143.1 40.4% 378.5 308.5 22.7% EBITDA (Cr) 10.1 9.0 12.2% 9.9 30.5 (67.5%) EBITDA margin % 5.0% 6.3% 2.6% 9.9% • Segment revenue registered a robust growth of 40.4% and 22.7% YoY in Q2 FY22 and H1 FY22
Slide 17: COVID-19 update
COVID -19 update: • Covid-19 cases declining steadily after a very harsh second wave of COVID-19 in Q1FY22 which impacted rural India. • GAVL’s focus was on employee safety and business continuity ❑ Vaccination - 100% of eligible employees have been vaccinated with at least one dose, 85% of employee
Slide 18: Strong commitment to CSR
Strong commitment to CSR GAVL CSR Strategy for H1 FY22 has been pivoted to strengthen the public healthcare system in order to address the challenges faced by rural communities in Second wave of Covid-19. A detailed needs assessment study has also been conducted to align our CSR initiatives with cha
Slide 19: GAVL Shareholding Pattern
GAVL SHAREHOLDING PATTERN Major Investors Shareholding pattern as on September 30, 2021 • Temasek Others , • LIC of India 8.1% DII, 5.5% • Kotak Mutual Fund • Aberdeen • DSP FII, 14.7% • Vanguard • Bajaj Holdings Promoters, 71.6% • Tata AIG • Quant Mutual Fund 18 I Godrej Agrovet
Slide 20: Contact Us
CONTACT US To know more, visit us at: www.godrejagrovet.com S Varadaraj Amit S Pendse Email: s.varadaraj@godrejagrovet.com Email: amit.pendse@godrejagrovet.com gavlinvestors@godrejagrovet.com gavlinvestors@godrejagrovet.com 19 I Godrej Agrovet
Slide 21: Disclaimer
DISCLAIMER Some of the statements in this communication may be forward looking statements within the meaning of applicable laws and regulations. Actual results might differ substantially from those expressed or implied. Important developments that could affect the Company’s operations include change
Slide 22: Thank you for your time and consideration
THANK YOU FOR YOUR TIME AND CONSIDERATION 21 I Godrej Agrovet